Raised £1.2m in October 2015 from a syndicate of UK business Angels to continue our work at developing High Content based personalized chemotherapy.
Moved to our new premises at City Labs 1.0 located in the heart of the Manchester Royal Infirmary, the most prominent hospital in Greater Manchester. Please see below for our new address details
Changing our name from Imagen Biotech to Imagen Therapeutics
Appointed Professor Justin Stebbing (Harley Street & Imperial College, London) as our honorary chief medical advisor.
Completed a 60 patient study in ovarian cancer and initial clinical match up data on the first 28 samples demonstrated an assay accuracy rate of 96%.
Part of the MasterPlans consortium to examine the personalization of LUPUS treatments.
Part of a consortium on a EU Framework 7 award: Rheumatoid arthritis and periodontal inflammatory disease.
Our sole aim is to help get the right chemotherapy to the right patient as fast as possible. We do this by measuring the effectiveness of a wide range of available chemotherapy drugs to kill a cancer sample that has been derived directly from the patient using a very modern technology known as High Content Analysis.
The short answer is lots. We routinely test 56 different therapies although even this is not an exhaustive list of the number of therapies on the market.
Very few!. If you are suffering from glioblastoma then your standard treatment option is radiotherapy and temozolomide. Even difficult to treat cancers which have been extensively researched still have surprisingly few treatment options. For example, ovarian cancer is mostly treated with either cisplatin, carboplatin, doxirubicin or some other standard chemotherapy combination.
Imagen Biotech is developing a test which aims to find the best chemotherapy for the patient out of all the available options on the market. Ultimately, we want to do this independent of whether the therapy we suggest is licensed for that particular patient's cancer. This strategy will allow patients, who are highly responsive to modern chemotherapies, to be effectively matched to these therapies hence improving their overall prognosis and quality of life.